Economical impact of orchiectomy for advanced prostate cancer

International Braz J Urol

Volumn 29, Issue 2, 2003, Pages 127-132

  Peclat de Paula, Adriano A ^a   Piccelli, Hilton R S ^a   Pinto, Nilson P ^a   Teles, Antonio G ^a   Franqueiro, Antonio G ^a   Maltez, Adriano R L ^a   Silva, Jose H ^a  

^a Araujo Jorge Hospital   (Brazil)

Author keywords

Androgen; Antogonists; Castration; Costs and cost analysis; Prostate; Prostatic neoplasms; Therapy

Indexed keywords

ANTIANDROGEN; ANTIBIOTIC AGENT; CEFAZOLIN; GONADORELIN DERIVATIVE; KETOPROFEN; PARACETAMOL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CASTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH ECONOMICS; HEMATOMA; HUMAN; MALE; MENTAL DISEASE; ORCHIECTOMY; POSTOPERATIVE PAIN; PROSTATE CANCER; SURGICAL TECHNIQUE; TREATMENT OUTCOME;

EID: 0037515748     PISSN: 16775538     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1677-55382003000200006     Document Type: Article

References (12)

1. Huggins C, Hodges CV: Studies on prostatic cancer: the effect of castration of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941; 1: 293-7.
2. Stricker HJ: Luteinizing hormone-releasing hormone antagonists in prostate cancer. Urology 2001; 58: 24-7.
3. Kolvenbag GJ, Iversen P: Anti-androgen monotherapy: a new form of treatment for patients with prostate cancer. Urology 2001; 58: 16-23.
4. Malkowics SB: The role of Diethylstilbestrol in the treatment of prostate cancer. Urology 2001; 58: 108-13.
5. Collette L, Studer UE: Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely shows statistically significant differences. Prostate 2001; 48: 29-39.
6. Schmitt B, Witt TJ: Combined androgen blockade with non-steroidal Anti-androgens for advanced prostate cancer: a systematic review. Urology 2001; 57: 727-32.
7. Chapman JP: Comparison of testosterone and LH values in subcapsular vs total orchiectomy patients. Urology 1987; 30: 27-8.
8. Hering FL, Dall'oglio MF, Caponero R, Rodrigues PR, Nesrallah LJ, Srougi M: Total versus subcapsular orchiectomy for treatment of advanced prostatic carcinoma: Comparison of serum testosterone and PSA levels. J Bras Urol. 1999; 25: 221-4 [in Portuguese].
9. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al.: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelein. N Engl J Med. 1997; 337: 295-300.
10. Benaim EA, Pace CM: Nadir prostate-specific antigen as a predictor to progression to androgen-independent prostate cancer. Urology 2002; 59: 73-8.
11. Nygard R, Norum J: Goserelin (Zoladex) or orchiectomy in metastatic Prostate cancer? A quality of life and cost-effectiveness analysis. Anticancer Res. 2001; 21: 781-8.
12. Mariani AJ, Glover M: Medical versus surgical androgen suppression therapy for prostate cancer: a 10-year longitudinal cost study. J Urol. 2001; 165: 104-7.